Century Therapeutics presents preclinical data for T1D therapy
Century Therapeutics Inc. (NASDAQ:IPSC) showcased nonclinical data for its potential type 1 diabetes treatment, CNTY-813, at the European Association for the Study of Diabetes' 62nd Annual Meeting in Milan, Italy. The therapy, derived from induced pluripotent stem cells, demonstrated the ability to maintain glycemic control in diabetic mice for over a year after graft removal.
CNTY-813 also proved effective in achieving normal blood sugar levels in streptozotocin-induced diabetic mice and exhibited potent glucose-stimulated insulin secretion, comparable to primary islets. The company reported that five clinical-scale batches produced a consistent final product profile over a 29-day process. In rat studies, CNTY-813 islets were found to engraft in the liver at one month post-transplant, with these islets expressing chromogranin A and insulin.
Cold-stored clinical-scale islets remained functional for 96 hours, and mice transplanted with these islets achieved normal blood glucose within 30 days, maintaining normoglycemia for three months post-transplant. Century Therapeutics has aligned with the FDA on its nonclinical package, Phase 1 manufacturing process, and proposed Phase 1/2 trial design for CNTY-813.
The company intends to submit an Investigational New Drug application for the therapy in the fourth quarter of 2026, contingent on the completion of additional studies. Initial safety and early efficacy data from the first-in-human CNTY-813 study are projected to be available in the second half of 2027. CNTY-813 is based on Century Therapeutics' Allo-Evasion 5.0 technology.
The biotechnology firm specializes in developing cell therapies for type 1 diabetes and other autoimmune conditions.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.